AZTA
AzentaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The bull case is that the May reset clears the deck: Sample Management still has resilient recurring pockets, UK Biocentre expands European sample-management capacity, liquidity remains strong, and a cleaner portfolio after B Medical plus better Multiomics execution could rebuild margins from depressed expectations.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Automated Stores rework costs and higher excess-and-obsolete inventory reserves are already hurting gross margin and could persist if execution does not improve.
Momentum
63
Value
61
Sentiment
21
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.00 · Bull $26.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $27.80
Why
Momentum63 · Δ7d +16.0
Value61 · Δ7d -0.1
Sentiment21 · Δ7d -5.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
63
26% active weight
Current posture
7d trendImproving
Δ7d
+16.0
Δ21d
-12.7
Value
61
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
21
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.1
Δ21d
-3.9
Why this grade
Composite grade D. Momentum 63.5 / Value 61.4 / Sentiment 21.2
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.21B
Beta
1.34
Shares Out
46.09M
P/E (TTM)
67.2
P/S (TTM)
2.77
P/FCF (TTM)
42.90
Rev YoY
+1.0%
EPS YoY
+234.9%
Gross Margin
+44.5%
Op Margin
-4.5%
Net Debt
-$283.35M
Current Ratio
2.83
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology